Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US
1. Bristol Myers Squibb will launch Cobenfy in the UK in 2026. 2. The UK price will match its US list price.
FAQ
Why Bullish?
The launch of a new treatment could enhance revenue, similar to previous launches that drove stock growth for BMY.
How important is it?
The article's focus on a new treatment launch indicates significant future revenue potential for BMY.
Why Long Term?
The launch is set for 2026, allowing time for revenue growth from this new market.